Pharmacokinetic disposition of marbofloxacin and danofloxacin in camel (Camelus dromedarius) - Anses - Agence nationale de sécurité sanitaire de l’alimentation, de l’environnement et du travail Access content directly
Journal Articles Journal of Camel Practice and Research Year : 2013

Pharmacokinetic disposition of marbofloxacin and danofloxacin in camel (Camelus dromedarius)

Lachguer M. A.
  • Function : Author
Mokhtari A.
  • Function : Author
Obelahcen R.
  • Function : Author
Attifi I.
  • Function : Author
El Hraiki A.
  • Function : Correspondent author
  • PersonId : 957716

Connectez-vous pour contacter l'auteur


The pharmacokinetic disposition of marbofloxacin and danofloxacin was studied in camels following a high - dosage administration as a single-dose (one shot) in a two-period crossover studies. Marbofloxacin was administred by intramuscular and intravenous routes @ 8mg/kg body weight. Danofloxacin was administred by sub-cutaneous and intravenous routes @ 6mg/kg body weight. Concentrations of both fluoroquinolones were measured by highperformance liquid chromatography and the data were subjected to kinetics analysis. The plasma disposition of marbofloxacin was best described by a tri-compartmental for intravenous and a bicompartmental open model with first-order for intramuscular dosing. The Peak plasma concentration (Cmax of 39.80 ± 11,29 mg/1 was reached at (Tma×) 1,16 ± 0,460 h after intamuscular administration. The elimination half-life (t1/2 β) and area under curve of concentration (AUQ were 11.97 ± 3.84 h and 320.65 ± 67.93 mg h/1, respectively. Danofloxacin achieved maximum plasma concentration (Cmax) after sub-cutaneous administration of 27.61 ± 5.00 mg/l at (Tmax) 2.54 ± 1.51h. The distribution half-life (t l/2 β) value of 33.77 ± 32.68 h was obtained for danofloxacin. These data were used together with in vivo pharmacokinetic parameters; Cmax and AUC to determine the surrogate markers of antimicrobial activity; C max/MIC and AUC/MIC Taking into account the values obtained for these markers, it was concluded that an intramuscular dose of 8 mg/kg of marbofloxacin and a sub-cutaneous dose of 6mg/kg of danofloxacin could be adequate for the treatment of infectious diseases caused by high susceptible bacteria such Mannheimia haemolytica and Pasteurella multocida in camels.
No file

Dates and versions

hal-01011381 , version 1 (23-06-2014)


  • HAL Id : hal-01011381 , version 1


Lachguer M. A., Mokhtari A., Obelahcen R., Attifi I., Michel Laurentie, et al.. Pharmacokinetic disposition of marbofloxacin and danofloxacin in camel (Camelus dromedarius). Journal of Camel Practice and Research, 2013, 20 (2), pp.245-250. ⟨hal-01011381⟩


141 View
0 Download


Gmail Facebook X LinkedIn More